Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Parmax Pharma Ltd - 540359 - Unaudited Financial Results For Quarter Ended 30Th June, 2022
Unaudited Financial Results for quarter ended 30th June, 2022 Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company
Board of Directors of the Company has, at its meeting held today, inter-alia, considered and approved the Unaudited Financial Results for quarter ended 30th June, 2022. Parmax Pharma Ltd - 540359 - Update on board meeting
The Board Meeting to be held on 11/08/2022 has been revised to 12/08/2022 Meeting of the Board of Directors of the Company is rescheduled on 12th August, 2022, the Friday to consider and approve Financial Results for the quarter ended 30th June, 2022. Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 ,inter alia, to consider and approve Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th June, 2022 Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- YASH VORADesignation :- Company Secretary and Compliance Officer Parmax Pharma Ltd - 540359 - Clarification On Price Movement.
Clarification on Price Movement.